Gabapentin/nabilone (PleoPharma)

加巴喷丁/大麻隆 (PleoPharma)

Report date: 2025/07/31 10:53:40

Base Information

Drug NameGabapentin/nabilone (PleoPharma)

Drug Alias NameNabilone/Gabapentin (PleoPharma)PP-01

ClassificationSmall molecules

Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 2 blockersVoltage-gated N-type calcium channel alpha-1B subunit blockersCannabinoid receptor agonists

TargetsVoltage-gated N-type calcium channel alpha-1B subunitVoltage-gated calcium channel alpha2/delta subunit 2Cannabinoid receptor

Therapy Area/IndicationsSubstance-Related Disorders

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Gabapentin Nabilone

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesPleoPharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesPleoPharma Inc

Inactive CompaniesN/A

Active IndicationsSubstance-Related Disorders

Inactive IndicationsN/A

Other Information

ATC CodeN/A